Dimensional Fund Advisors LP Raises Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Dimensional Fund Advisors LP grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,326,992 shares of the medical equipment provider’s stock after purchasing an additional 124,739 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Hologic were worth $172,780,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Innealta Capital LLC bought a new stake in shares of Hologic during the second quarter valued at approximately $25,000. iA Global Asset Management Inc. bought a new stake in shares of Hologic during the 1st quarter valued at $37,000. Mather Group LLC. bought a new stake in shares of Hologic during the 1st quarter valued at $48,000. Massmutual Trust Co. FSB ADV grew its position in shares of Hologic by 24.7% in the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 137 shares during the period. Finally, Toth Financial Advisory Corp increased its stake in shares of Hologic by 81.1% in the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 347 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

HOLX opened at $81.39 on Friday. The company’s 50-day simple moving average is $80.74 and its two-hundred day simple moving average is $77.05. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. The stock has a market capitalization of $18.99 billion, a P/E ratio of 41.53, a P/E/G ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the firm earned $0.93 earnings per share. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. As a group, analysts predict that Hologic, Inc. will post 4.09 EPS for the current year.

Insider Buying and Selling

In other Hologic news, insider Brandon Schnittker sold 476 shares of the stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. Insiders sold 18,280 shares of company stock valued at $1,469,973 over the last 90 days. Company insiders own 1.75% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on HOLX shares. StockNews.com downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. raised their price objective on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Stephens reissued an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. Evercore ISI raised their price target on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Tuesday, July 30th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $82.00 price target on shares of Hologic in a research report on Friday, August 16th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.